[Activity Repor] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)
date : 11/2/2022
Tags: AMR
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery, for which AMR Alliance Japan (Secretariat: HGPI) is a cooperating member, has released recommendations on “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.”
The recommendation can be found here.
*Available Only in Japanese
■The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery is comprised of The Japanese Society of Chemotherapy, The Japanese Association for Infectious Disease, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society for Bacteriology, The Pharmaceutical Society of Japan, and The Japanese Society of Veterinary Science. It investigates the promotion of infectious disease therapy and drug therapy from a medical perspective.
■AMR Alliance Japan
AMR Alliance Japan AMR was established in November 2018 as a multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of August 2022, its members include MSD K.K., “Kodomo to Iryo” Project, Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, NISSUI Pharmaceutical Co., Ltd., Nippon Becton Dickson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japanese Society of Hospital Pharmacists, The Pharmaceutical Society of Japan; The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.
日本語
Top Research & Recommendations Posts
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Policy Recommendations] Dementia Prevention Initiatives for Achieving a Dementia-Friendly and Inclusive Society (March 26, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Three Necessary Perspectives for Formulating the Basic Plan for the Promotion of Policies on Dementia: Creating a Society That is Inclusive for All People at All Times (April 1, 2024)
- [Policy Recommendations] Establishing an integrated care system for pain from the perspectives of people with lived experience (March 29, 2024)
Featured Posts
-
2024-04-02
[Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
-
2024-04-08
[Event Report] HGPI Participates in the Connecting Climate Minds Global Event (March 19-21, 2024)
-
2024-04-08
[Registration Open] The 124th HGPI Seminar “Reconsidering Infectious Disease Control Strategies Centering on Vaccination and Immunization – From the Experiences of the COVID-19 Pandemic and a Life Course Approach” (April 26, 2024)
-
2024-04-10
[Research Report] “International comparison of dementia policies, research study on information dissemination.” (April 10, 2024)
-
2024-04-11
[Research Paper] “Exploring the Potential of Industry-Academia-Civil Collaboration for Sustainability in the Healthcare Sector” Published in Journal Society for Environmental Economics and Policy Studies (March 31, 2024)